Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

被引：1

作者：

Papadimitrakopoulou, Vassiliki ^{[1
]}

Redman, Mary ^{[2
]}

Gandara, David R. ^{[3
]}

Hirsch, Fred R. ^{[4
]}

Mack, Philipp ^{[5
]}

Borghaei, Hossein ^{[6
]}

Langer, Corey ^{[7
]}

Wade, James ^{[8
]}

Edelman, Martin ^{[9
]}

Albain, Kathy ^{[10
]}

Lara, Primo ^{[5
]}

Aggarwal, Charu ^{[11
]}

Socinski, Mark ^{[12
]}

Gettinger, Scott ^{[13
]}

Bazhenova, Lyudmila ^{[14
]}

Malik, Shakun ^{[15
]}

Miller, Vincent ^{[16
]}

Mcdonough, Shannon ^{[17
]}

Sigal, Ellen V. ^{[2
]}

Kelly, Karen ^{[18
]}

Herbst, Roy ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Friends Canc Res, Washington, DC USA

[3] UC Davis Comprehens Canc Ctr, Div Hem Oncol, Sacramento, CA USA

[4] Univ Colorado, Ctr Canc, Other, Aurora, CO USA

[5] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[6] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] Univ Penn Hlth Syst, Hematol Oncol, Philadelphia, PA USA

[8] Heartland Ncorp, Decatur, IL USA

[9] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA

[10] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Div Hematol Oncol, Maywood, IL USA

[11] Univ Penn, Hematol Oncol, Philadelphia, PA 19104 USA

[12] Univ Pittsburgh, Med, Pittsburgh, PA USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] NCI, Ctep, NIH, Rockville, MD USA

[16] Fdn Med Inc, Clin Dev, Cambridge, MA USA

[17] Swog Stat Ctr, Seattle, WA USA

[18] UC Davis Comprehens Canc Ctr, Hematol Oncol, Sacramento, CA USA

[19] Yale Canc Ctr, Med Oncol, New Haven, CT USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

genomic screening; umbrella trial; S1400; Squamous cell lung cancer;

D O I：

10.1016/j.jtho.2016.11.513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA16.10

引用

页码：S439 / S440

页数：2

共 47 条

[31] SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Edelman, Martin J.
Redman, Mary W.
Albain, Kathy S.
McGary, Eric C.
Rafique, Noman M.
Petro, Daniel
Waqar, Saiama N.
Minichiello, Katherine
Miao, Jieling
Papadimitrakopoulou, Vassiliki A.
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1853 - 1859
[32] A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).
Riess, Jonathan W.
Redman, Mary Weber
Wheatley-Price, Paul
Faller, Bryan A.
Villaruz, Liza C.
Corum, Larry R.
Gowda, Aruna C.
Srkalovic, Gordan
Osarogiagbon, Raymond U.
Baumgart, Megan Ann
Qian, Lu
Minichiello, Katherine
Gandara, David R.
Herbst, Roy S.
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
Bazhenova, Lyudmila
Redman, Mary Weber
Gettinger, Scott N.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence Howard
Gandara, David R.
Bradley, Jeffrey D.
Stinchcombe, Tom
Leighl, Natasha B.
Ramalingam, Suresh S.
Tavernier, Susan S.
Minichiello, Katherine
Kelly, Karen
Papadimitrakopoulou, Vassiliki
Herbst, Roy S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[34] A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.
Wade, James Lloyd
Langer, Corey J.
Redman, Mary
Aggarwal, Charu
Bradley, Jeffrey D.
Crawford, Jeffrey
Miao, Jieling
Griffin, Katie
Herbst, Roy S.
Kelly, Karen
Gandara, David R.
Papadimitrakopoulou, Vassiliki
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).
Waqar, Saiama Naheed
Redman, Mary Weber
Arnold, Susanne M.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence Howard
Gandara, David R.
Stinchcombe, Tom
Leighl, Natasha B.
Ramalingam, Suresh S.
Tanna, Saloni H.
Raddin, Ryan S.
Minichiello, Katherine
Kelly, Karen
Bradley, Jeffrey D.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)
Roth, Joshua A.
Trivedi, Meghna S.
Gray, Stacy W.
Patrick, Donald L.
Delaney, Debbie M.
Watabayashi, Kate
Litwin, Paul
Shah, Parth
Crew, Katherine D.
Yee, Monica
Redman, Mary W.
Unger, Joseph M.
Papadimitrakopoulou, Vassiliki
Johnson, Judy
Kelly, Karen
Gandara, David
Herbst, Roy S.
Hershman, Dawn L.
Ramsey, Scott D.
JCO ONCOLOGY PRACTICE, 2021, 17 (11) : 692 - +
[37] SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Langer, Corey J.
Redman, Mary W.
Wade, James L., III
Aggarwal, Charu
Bradley, Jeffrey D.
Crawford, Jeffrey
Stella, Philip J.
Knapp, Mark H.
Miao, Jieling
Minichiello, Katherine
Herbst, Roy S.
Kelly, Karen
Gandara, David R.
Papadimitrakopoulou, Vassiliki A.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1839 - 1846
[38] Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Leighl, Natasha B.
Redman, Mary W.
Rizvi, Naiyer
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence H.
Wade, James L.
Irvin, William J.
Reddy, Sreekanth C.
Crawford, Jeffrey
Bradley, Jeffrey D.
Stinchcombe, Thomas E.
Ramalingam, Suresh S.
Miao, Jieling
Minichiello, Katherine
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki A.
Kelly, Karen
Gandara, David R.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
[39] Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI
Reckamp, K.
Redman, M. W.
Dragnev, K.
Villaruz, L.
Faller, B.
Al Baghdadi, T.
Hines, S.
Minichiello, K.
Gandara, D. R.
Kelly, K.
Herbst, R. S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1033 - S1033
[40] SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
Leighl, Natasha B.
Redman, Mary Weber
Rizvi, Naiyer A.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence Howard
Wade, James Lloyd
Irvin, William Johnson
Reddy, Sreekanth
Crawford, Jeffrey
Bradley, Jeffrey D.
Stinchcombe, Tom
Ramalingam, Suresh S.
Miao, Jieling
Minichiello, Katherine
Gandara, David R.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →